相关实验视频

Updated: May 5, 2026

Qualitative and Quantitative Assays for Detection and Characterization of Protein Antimicrobials

Qualitative and Quantitative Assays for Detection and Characterization of Protein Antimicrobials

Published on: April 10, 2016

素染料使用的多米克辛的肠道剂型的全绿定位:应用到内容统一性测试

Mahmoud A Abdelmajed¹, Khalid M Badr El-Din², Tamer Z Attia³

¹Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Deraya University, New Minia, Egypt. Mahmoud.alaa81@yahoo.com.

|August 27, 2024

概括

一种新的,环保的光谱光度测量方法量化了素和多素B类抗生素. 这种绿色分析技术成功地测量了这些关键药物的亲肠道形式,解决了关键的治疗需求.

科学领域:

分析化学分析化学
药品分析药品分析
绿色化学绿色化学

背景情况:

由于治疗替代方案有限,多胺,包括胆固醇素 (多胺E) 和多胺B,是重要的抗生素.
它们的复苏对于关键感染是必要的,这凸显了对可靠量化方法的需求.

研究的目的:

开发和验证一种简单的,绿色的,非提取的光谱光度法,用于量化素和多素B.
首次采用这种方法来确定这些抗生素的亲肠道剂量形式.

主要方法:

一种光谱光度学方法,利用与乙氨酸B的离子对复合体形成.
优化反应条件,包括pH值,缓冲体积,乙氨酸度和反应时间.
方法根据国际协调理事会 (ICH) 的指导方针进行验证.

主要成果:

该方法涉及形成一个粉红色的离子对复合体,在558 nm检测到,没有有机溶剂.
贝尔-兰伯特定律在胆固醇素的度范围为1-6微克/毫升,聚米辛B的度范围为1-9微克/毫升.
这种技术在被应用到亲肠道配方时,包括内容统一性测试在内,显示出出色的恢复效果.

结论:

一种新的,环保的光谱光度测量方法,用于胆素和多素B的量化已经成功开发和验证.
这种方法提供了一种可靠和有效的方法来分析这些必不可少的抗生素在其制药剂量形式.

关键词:

胆固醇素 (多氨基素E) 是一种内容统一性测试内容统一性测试红素B 红素B 亲肠道用药形式的剂量形式波利米克辛B是一种多重的物质.聚米克辛是多种类型的.

更多相关视频

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

相关概念视频

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...